Phio Pharmaceuticals (PHIO)

• Market cap: $10.9M
• 1 day: -8.10%
• 5 days: -26.77%
• 1 month: 19.47%
• 3 months: 70.68%
• 6 months: -19.22%
• Year to date: 19.47%
• 1 year: -65.45%
• 5 years: -99.15%
• 10 years: -99.91%
• Sector: Healthcare
• Industry: Biotechnology

About: Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Employees: 5

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0% more funds holding

Funds holding: 11 [Q4 2024] → 11 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

6.8% less ownership

Funds ownership: 8.9% [Q4 2024] → 2.11% (-6.8%) [Q1 2025]

53% less capital invested

Capital invested by funds: $277K [Q4 2024] → $131K (-$146K) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 76% upside
• Avg. target: $9 296% upside
• High target: $14 517% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis	517% upside $14	Buy Assumed	5 Jun 2025
HC Wainwright & Co. Vernon Bernardino	76% upside $4	Buy Reiterated	8 Apr 2025